Curocell Inc. (KOSDAQ:372320)

South Korea flag South Korea · Delayed Price · Currency is KRW
36,600
+600 (1.67%)
At close: Aug 13, 2025, 3:30 PM KST
1.67%
Market Cap526.32B
Revenue (ttm)n/a
Net Income (ttm)-35.47B
Shares Out14.38M
EPS (ttm)-2,511.78
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume110,976
Average Volume74,884
Open36,600
Previous Close36,000
Day's Range36,150 - 37,750
52-Week Range19,390 - 39,000
Betan/a
RSI59.50
Earnings DateAug 13, 2025

About Paramount Global

Curocell Inc. develops CAR-T cell therapy for the treatment of cancer. It focuses on the development of CD19 CAR-T for the treatment of lymphoma; and BCMA CAR-T for the treatment of multiple myeloma. The company was incorporated in 2016 and is based in Daejeon, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Employees 136
Stock Exchange KOSDAQ
Ticker Symbol 372320
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.